Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Adult
Aged
Aged, 80 and over
Blood Specimen Collection
/ methods
CA-19-9 Antigen
/ blood
Carcinoma, Pancreatic Ductal
/ blood
Case-Control Studies
Datasets as Topic
Early Detection of Cancer
/ methods
Feasibility Studies
Female
Humans
Male
MicroRNAs
/ blood
Middle Aged
Neoplasm Staging
Pancreas
/ pathology
Pancreatic Neoplasms
/ blood
ROC Curve
Young Adult
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
11
06
2020
revised:
11
12
2020
accepted:
21
04
2021
pubmed:
25
4
2021
medline:
11
3
2022
entrez:
24
4
2021
Statut:
ppublish
Résumé
Early detection of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcomes; however, PDAC is usually diagnosed late. Therefore, blood-based minimally invasive biomarker assays for limited volume clinical samples are urgently needed. A novel miRNA profiling platform (Abcam Fireplex-Oncology Panel) was used to investigate the feasibility of developing early detection miRNA biomarkers with 20 μL plasma from a training set (58 stage II PDAC cases and 30 controls) and two validation sets (34 stage II PDAC cases and 25 controls; 44 stage II PDAC cases and 18 controls). miR-34a-5p [AUC = 0.77; 95% confidence interval (CI), 0.66-0.87], miR-130a-3p (AUC = 0.74; 95% CI, 0.63-0.84), and miR-222-3p (AUC = 0.70; 95% CI, 0.58-0.81) were identified as significantly differentially abundant in plasma from stage II PDAC versus controls. Although none of the miRNAs individually outperformed the currently used serologic biomarker for PDAC, carbohydrate antigen 19-9 (CA19-9), combining the miRNAs with CA 19-9 improved AUCs from 0.89 (95% CI, 0.81-0.95) for CA 19-9 alone to 0.92 (95% CI, 0.86-0.97), 0.94 (95% CI, 0.89-0.98), and 0.92 (95% CI, 0.87-0.97), respectively. Gene set enrichment analyses of transcripts correlated with high and low expression of the three miRNAs in The Cancer Genome Atlas PDAC sample set. These miRNA biomarkers, assayed in limited volume plasma together with CA19-9, discriminate stage II PDAC from controls with good sensitivity and specificity. Unbiased profiling of larger cohorts should help develop an informative early detection biomarker assay for diagnostic settings. PREVENTION RELEVANCE: Development of minimally invasive biomarker assays for detection of premalignant disease and early-stage pancreatic cancer is key to improving patient survival. This study describes a limited volume plasma miRNA biomarker assay that can detect early-stage resectable pancreatic cancer in clinical samples necessary for effective prevention and clinical intervention.
Identifiants
pubmed: 33893071
pii: 1940-6207.CAPR-20-0303
doi: 10.1158/1940-6207.CAPR-20-0303
pmc: PMC8818322
mid: NIHMS1699021
doi:
Substances chimiques
CA-19-9 Antigen
0
MicroRNAs
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
729-740Subventions
Organisme : NCI NIH HHS
ID : U01 CA200468
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA200466
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA252965
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA196403
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA217789
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221707
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA214263
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES030285
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
PLoS One. 2015 Oct 02;10(10):e0139049
pubmed: 26431551
Biochem Soc Trans. 2015 Dec;43(6):1208-14
pubmed: 26614662
Hematol Oncol Clin North Am. 2015 Aug;29(4):701-16
pubmed: 26226905
Pancreas. 1987;2(4):398-403
pubmed: 3306667
Cell Cycle. 2008 Aug 15;7(16):2591-600
pubmed: 18719384
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Insights Imaging. 2020 Apr 25;11(1):58
pubmed: 32335790
BMC Genomics. 2018 May 5;19(1):331
pubmed: 29728066
Mol Cell. 2014 Oct 2;56(1):104-15
pubmed: 25263593
J Natl Cancer Inst. 2020 Nov 1;112(11):1162-1169
pubmed: 31958122
PLoS One. 2015 Jan 21;10(1):e0116869
pubmed: 25607660
Genome Res. 2009 Jan;19(1):92-105
pubmed: 18955434
Int J Cancer. 2010 Jan 1;126(1):73-80
pubmed: 19551852
Blood. 2013 Jun 20;121(25):4977-84
pubmed: 23550041
Eur J Surg. 1993 Feb;159(2):101-7
pubmed: 8098623
Sci Rep. 2017 Mar 23;7:44986
pubmed: 28332581
Elife. 2017 Oct 31;6:
pubmed: 29087294
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancer Prev Res (Phila). 2009 Sep;2(9):807-13
pubmed: 19723895
Proc Natl Acad Sci U S A. 1985 Jun;82(11):3535-8
pubmed: 3858838
Ann Surg Oncol. 2014 Jul;21(7):2453-62
pubmed: 24609291
Transl Oncol. 2018 Aug;11(4):883-889
pubmed: 29783093
Br J Cancer. 2007 Feb 12;96(3):507-9
pubmed: 17224924
Mol Cell. 2007 Jun 8;26(5):745-52
pubmed: 17540599
J Cancer. 2015 Oct 16;6(12):1230-5
pubmed: 26535064
Dev Cell. 2006 Oct;11(4):441-50
pubmed: 17011485
Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8
pubmed: 17991681
Life Sci. 2020 May 1;248:117473
pubmed: 32114007
Surgery. 2017 Jul;162(1):104-111
pubmed: 28238344
Science. 2009 Sep 18;325(5947):1555-9
pubmed: 19661383
Pancreas. 2016 Jan;45(1):84-92
pubmed: 26262588
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Methods. 2013 Jan;59(1):S1-6
pubmed: 23036329
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376184
Nature. 2020 Feb;578(7795):449-454
pubmed: 32051587
PLoS One. 2011 Apr 07;6(4):e18613
pubmed: 21490936
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Nat Rev Genet. 2011 Feb;12(2):99-110
pubmed: 21245828
J Surg Oncol. 2007 Feb 1;95(2):142-7
pubmed: 17262731
Gastroenterology. 2008 Apr;134(4):981-7
pubmed: 18395079
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Clin Chem. 1999 Jan;45(1):54-61
pubmed: 9895338
Pancreatology. 2018 Dec;18(8):862-867
pubmed: 30249386
Nat Commun. 2018 Jan 2;9(1):16
pubmed: 29295989
Nature. 2012 Nov 15;491(7424):399-405
pubmed: 23103869
Methods Mol Biol. 2017;1654:209-219
pubmed: 28986792
Neuroendocrinology. 2015;101(2):133-42
pubmed: 25613442
Curr Drug Targets. 2012 Dec;13(14):1750-6
pubmed: 23140286
J Gastroenterol Hepatol. 2004 Feb;19(2):182-6
pubmed: 14731128
Semin Cell Dev Biol. 2018 Jun;78:22-36
pubmed: 29258963
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Sci Rep. 2017 Feb 01;7:38232
pubmed: 28145431
Cell. 2012 Apr 27;149(3):656-70
pubmed: 22541435
J Am Coll Radiol. 2017 Nov;14(11S):S560-S569
pubmed: 29101993
Clin Cancer Res. 2015 Feb 1;21(3):622-31
pubmed: 24938522
Med Oncol. 2013 Dec;30(4):700
pubmed: 24026657
Int J Clin Oncol. 2001 Feb;6(1):50-4
pubmed: 11706528
Genomics Proteomics Bioinformatics. 2012 Oct;10(5):246-53
pubmed: 23200134